Study on correlation between PKIB and pAkt expression in breast cancer tissues

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Breast cancer remains a significant global health challenge.
• Understanding molecular mechanisms driving breast cancer progression is crucial for developing targeted therapies.
• The Akt signaling pathway is frequently dysregulated in various cancers, including breast cancer.

Purpose of the Study:

• To investigate the expression of cyclic AMP (cAMP) dependent protein kinase inhibitor (PKIB) in human breast cancer tissues.
• To determine the correlation between PKIB expression and phosphorylated protein kinase B (pAkt) levels.
• To explore the association of PKIB expression with different breast cancer subtypes and clinical pathological factors.

Main Methods:

• Immunohistochemistry was used to detect PKIB, pAkt, estrogen receptor (ER), progesterone receptor (PR), and HER2 expression in 148 primary breast cancer tissue samples.
• The Allred score was employed for classification.
• Statistical analysis was performed on clinical pathological factors, and PKIB/pAkt expression was analyzed across luminal A, luminal B, HER2+/ER-, and triple-negative breast cancer subtypes.

Main Results:

• A significant positive correlation was observed between PKIB expression and pAkt positivity in tumor tissues (p<0.05).
• PKIB and pAkt showed positive staining in the cytoplasm.
• PKIB expression was significantly associated with triple-negative breast cancer (p<0.05) but not with other clinical pathological factors.

Conclusions:

• Cytoplasmic PKIB expression in breast tumors is closely linked to pAkt signaling and triple-negative breast cancer.
• PKIB appears to promote breast tumor development by modulating the Akt signaling pathway.
• PKIB represents a potential therapeutic target for breast cancer, particularly for triple-negative subtypes.